Abstract
Cutaneous lymphomas encompass a broad spectrum of malignancies, including both primary and secondary cutaneous lymphomas. Determining the exact subtype of cutaneous lymphoma offers prognostic importance and directs therapeutic decisions. We describe the case of a 67-year-old woman with cutaneous involvement of splenic marginal zone lymphoma successfully treated with rituximab and bendamustine. We discuss the diagnostic work-up, including the histopathologic findings and treatment of this disease.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bendamustine Hydrochloride
-
Biomarkers, Tumor / analysis
-
Biopsy
-
Female
-
Humans
-
Immunohistochemistry
-
Lymphoma, B-Cell, Marginal Zone / chemistry
-
Lymphoma, B-Cell, Marginal Zone / drug therapy
-
Lymphoma, B-Cell, Marginal Zone / pathology*
-
Nitrogen Mustard Compounds / administration & dosage
-
Predictive Value of Tests
-
Remission Induction
-
Rituximab
-
Skin Neoplasms / chemistry
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / secondary*
-
Splenic Neoplasms / chemistry
-
Splenic Neoplasms / drug therapy
-
Splenic Neoplasms / pathology*
-
Time Factors
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Biomarkers, Tumor
-
Nitrogen Mustard Compounds
-
Rituximab
-
Bendamustine Hydrochloride